VEGF Trap – Eye CLEAR-IT 2 Final Primary Endpoint Results

A Phase 2, Randomized, Controlled Dose- and Interval-Ranging Study c Intravitreal VEGF Trap-Eye in Patien with Neovascular Age-Related Macul Degeneration Mylan v. Regeneron, IP

U.S. Pat. 9,669,069, E

Find authenticated court documents without watermarks at docketalarm.com.

Disclosures

- Commercial relationships
 J. Heier, Regeneron financial support
- Trial registration
 www.clinicaltrials.gov (NCT00320788)




Find authenticated court documents without watermarks at docketalarm.com.

Angiogenesis Inhibition via VEGF Blog Unmet Medical Needs Remain Despite Advances in Treatment of Wet AM

- Ranibizumab (LUCENTIS[®]*) represents a major advance AMD treatment
 - The approved regimen of ranibizumab in the U.S., 0.5 mg adr monthly, resulted in the following results at 1 year:¹
 - Prevention of moderate vision loss in 95-96% of patients
 - A \geq 15 letter (3-line) gain in 34- 40% of patients
 - Mean improvement in visual acuity of 7.2-11.3 letters (~6-10 at mo
 - Vision of \geq 20/40 in 39-40% of patients
 - Vision of ≤20/200 in only 12-16% of patients
- A clinical need remains for an agent that can further improve
 - Further improvement in visual acuity
 - More patients with vision of $\geq 20/40$
 - Fewer patients with vision of $\leq 20/200$
- A clinical need remains for an agent that improves and ma visual acuity with a dosing schedule requiring less than m injections

* LUCENTIS[®] is a registered trademark of GENENTECH, Inc
1 Rosenfeld, et al., *N Engl. J Med.*, 2006 355(14):1419-31; Brown, et al., *N Engl. J Med.*, 2006

VEGF Trap-Eye*: A Unique VEGF Blocker



- Fusion protein of ke human VEGF receptor human IgG Fc
- Contains all human sequences
- High affinity and bine tightly than native rec monoclonal antibody
- Blocks all VEGF-A is
 Placental Growth Fac
- Penetrates all layers (MW ~110,000)

*VEGF Trap–Eye is specially purified and formulated for intravitreal injection. IgG=immunoglobulin G; MW=molecular weight; VEGF=vascular endothelial growth factor;

CLEAR-IT 2 Study Objective

- Primary objectives:
 - Assess the effect of intravitreal VEGF Trap-Ey retinal thickness
 - Assess ocular and systemic safety and tolerak repeated IVT doses of VEGF Trap-Eye in wet
- Secondary objective:

 Assess the effect of IVT VEGF Trap-Eye on be corrected visual acuity in ETDRS letters

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.